Nuwellis secures exclusive U.S. rights for Zorro-Flow, a non-invasive pediatric urine collection system.

Nuwellis, Inc. has obtained exclusive U.S. distribution rights for the Zorro-Flow pediatric urine collection system, a non-invasive device designed for neonates and small children to improve urine output monitoring and early kidney injury detection. This agreement expands Nuwellis' pediatric portfolio and complements its existing products like Aquadex SmartFlow and AtriAmp, enhancing its presence in pediatric critical care. Commercialization in the U.S. is set to begin in early 2027, leveraging Nuwellis' established relationships with children's hospitals. The device offers a safer, more effective alternative to traditional urine collection methods, reducing pain and infection risks for vulnerable patients.

Following Nuwellis' announcement of exclusive U.S. distribution rights for the Zorro-Flow pediatric urine collection system, the company's stock on Pluang is trading at USD 4.92 as of Nov 10, 2026 20:42 WIB, showing a slight decline of 0.40% in the past day. The market cap stands at $1.99 million, with a typical hold time of 32 days among Pluang investors. Notably, current order activity leans heavily toward selling, with 83% of orders being sell and 17% buy, reflecting cautious market sentiment.